2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH DENA BATTLE
Patient Perspectives on Cytoreductive Nephrectomy after the CARMENA Trial

VIEW ALL ASCO GU 2019 VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH OLIVER SARTOR
Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer

VIEW ALL PCF VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH KARIM FIZAZI
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC

VIEW ALL ASCO GU 2019 VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH JAMES GULLEY
Immunotherapy Across Genitourinary Malignancies

VIEW ALL ASCO GU 2019 VIDEOS

Featured Videos

#AUA14 - Neutrophil-to-lymphocyte ratio (NLR): Prognostic indicator for overall survival (OS) in patients undergoing radical cystectomy (RC) - Session Highlights

ORLANDO, FL USA (UroToday.com) - Inflammatory markers are known to predict outcomes in patients with hepatic, gastric, pancreatic, and kidney cancers. As such, authors sought to confirm initial data regarding the prognostic relevance of preoperative NLR for OS in patients undergoing RC for urothelial carcinoma of bladder. A retrospective analysis on the Fox Chase Cancer Center institutional bladder cancer database was performed and identified patients who underwent radical cystectomy from 2006 to 2011. Patients with available preoperative hematologic parameters for absolute lymphocyte and neutrophil count, within 1 month of RC, were included in the analysis. As previously reported, NLR ≥ 2.5 was considered abnormal. Prognostic value of preoperative NLR was evaluated by univariate and multivariable Cox and Fine & Gray proportional hazard ratios to assist in risk stratification for OS.

auaThree hundred fourteen patients met eligibility criteria. Median follow-up was 29.5 months (IQR=38.8). The majority of patients were Caucasian (90%) men (73%), with median age of 69. Thirty-two percent,17%, 30%, 21%, and 22% had pathologic stage T1,T2,T3,T4, and node positive disease, respectively. While 49% received neoadjuvant chemotherapy, 35% of patients developed recurrent disease at a median follow-up of 10 months following RC. The 2- and 5- year OS rates were 72% and 41%, respectively. In multivariable analysis, independent of T-stage, N-stage, age, race, gender, receipt of chemotherapy, NLR > 2.5 was associated with inferior overall survival (HR 1.8 [CI 1.2−2.7], p=0.007).

mehrazin fccc nlr fig1 thumbOver the last decade, there has been increasing evidence that cancer-related inflammation is a major determinant of outcome in cancer patients. The systemic inflammation initiated by tumors known to cause apoptosis and/or margination of the white blood cells leading to a drop in lymphocytes, and perhaps this tumor-associated immune dampening is one of the reasons for poor survival in cancer patients. Here, as shown for various other cancers, NLR was found to be an independent prognostic factor in bladder cancer patients treated with RC . Further investigation into whether NLR can be harnessed for purposes of clinical prognostication and individualized patient care appears warranted.


Presented by Reza Mehrazin, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Fox Chase Cancer Center, Philadelphia, PA USA

Written by Reza Mehrazin, MD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 3 Issue 4

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe